In human breast cancer cells, the treatment with adenosine 5′-(α,β-methylene)diphosphate (APCP), a competitive CD73 inhibitor, decreased proliferation rate and cell viability induced by CD73 overexpression (Ref. Here, NT5E is linked to breast carcinoma.